Watermark Medical makes an at-home headset called ARES that uses sensors to measure oxygen saturation, pulse, head movement and head position and combines that data with questionnaire responses to indicate sleep apnea risk. The company recently merged with sleep diagnostics provider SleepMed. According to the article, the ARES device has been tested in 100,000 patients since 2010. Watermark says its technology is intended to move sleep apnea testing out of expensive labs and into primary care. Insurer reimbursement changes have driven a broader industry push toward at-home testing, and the market for sleep-apnea diagnostics and treatments is becoming more competitive. Competitors mentioned include Cleveland Medical Devices, Itamar Medical and NovaSom. Watermark Medical develops a SaaS-based home sleep testing (HST) platform for the sleep-disordered breathing market. Its product, the Watermark ARES, enables medical practitioners to manage, aggregate and access critical diagnostic and historical patient information. The company sells and distributes the ARES through partners including PSS Medical, McKesson Corporation and Henry Schein. Watermark will use the new financing to further deploy its SaaS system across the sleep-disordered breathing market. The company is headquartered in Boca Raton, Florida. Watermark Medical develops medical products and services for diagnosing and managing sleep-disordered breathing. Its flagship product, the Watermark ARES (Apnea Risk Evaluation System), is an FDA-cleared wireless ambulatory sleep test device used to help diagnose obstructive sleep apnea. The company’s technology enables medical practitioners to access, manage, and aggregate critical diagnostic and historical patient information. The $15M equity investment from CA Technologies is intended to further develop that existing technology. CA and Watermark plan to collaborate to develop cloud-connected healthcare solutions. CA will take a minority stake in the company and hold two seats on Watermark’s board.

Total raised

$53M

Funding rounds

3

Latest round

Equity

Latest activity

Apr 2013